STASEY confirms safety, efficacy of emicizumab for PwHA with FVIII inhibitors
16 Aug 2021
byAudrey Abella
The STASEY trial, a large, phase IIIb study evaluating a diverse population of persons with haemophilia A (PwHA) with Factor(F)VIII inhibitors, confirms the safety and efficacy profile of the bispecific monoclonal antibody emicizumab that has been demonstrated in the HAVEN trials.
